The spike protein of the mutant strain is slightly different from the original snout. But biopsy interferometry studies show that the study antibody binds to the mutant spike protein with the same affinity to the original virus, XBiotech reported.
The company’s True Human platform focuses on interleukin 1 alpha (IL-1a). For COVID-19, XBiotech is developing antibody therapy derived from people who have contracted the coronavirus and have no history of severe infection. The idea behind development is that anti-IL-1a treatment works on the inflammatory response induced by cytokine storm in severe COVID-19 cases.
XBiotech antibodies are currently at a preclinical stage of development.
Copyright © 2021 scienceboard.net